8 hospitals of the Catholic University of Korea with high-volume percutaneous coronary intervention of following hospitals are participating in the current study.~Seoul St. Mary's Hospital, Seoul, South Korea~Yeoido St. Mary's Hospital, Seoul, South Korea~Uijongbu St. Mary's Hospital, Gyeonggi-do, South Korea~Eunpyeong St. Mary's Hospital, Seoul, South Korea~Bucheon St. Mary's Hospital, Gyeonggi-do, South Korea~Incheon St. Mary's Hospital, Incheon, South Korea~St. Vincent Hospital, Gyeonggi-do, South Korea~Daejeon St. Mary's Hospital, Daejeon, South Korea~After recruitment of all patients, the control group will be selected from a previous prospective cohort (COREA-AMI, NCT02385682) using identical inclusion / exclusion criteria except for use of SGLT2 inhibitors. The control cohort of 3,000 patients will be selected using 1:3 propensity matching.
Prospective trials performed on type 2 diabetes patients without established cardiovascular disease has shown that SGLT2 inhibitors reduce cardiovascular risk. No studies have yet examined the occurrence of cardiovascular disease in patients with acute myocardial infarction.~The investigators designed the current study to evaluate the most ideal oral hypoglycemic agent in type 2 diabetes patients undergoing percutaneous coronary intervention for acute myocardial infarction. The investigators hypothesize that the use of SGLT-2 inhibitors will reduce cardiovascular events and modify left ventricular remodeling after myocardial infarctions.